###begin article-title 0
###xml 37 43 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11</italic>
###xml 69 74 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
Regulation of TGF-beta signalling by Fbxo11, the gene mutated in the Jeff otitis media mouse mutant
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11</italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 472 477 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
Jeff is a dominant mouse mutant displaying chronic otitis media. The gene underlying Jeff is Fbxo11, a member of the large F-box family, which are specificity factors for the SCF E3 ubiquitin ligase complex. Jeff homozygotes die shortly after birth displaying a number of developmental abnormalities including cleft palate and eyes open at birth. TGF-beta signalling is involved in a number of epithelial developmental processes and we have investigated the impact of the Jeff mutation on the expression of this pathway.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 225 231 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2 </italic>
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 387 394 387 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2</italic>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 536 540 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 603 608 603 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 189 193 <span type="species:ncbi:10090">Mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
Phospho-Smad2 (pSmad2) is significantly upregulated in epithelia of Jeff homozygotes. Moreover, there was a significant increase in nuclear localization of pSmad2 in contrast to wild type. Mice heterozygous for both Jeff and Smad2 mutations recapitulate many of the features of the Jeff homozygous phenotype. However, tissue immunoprecipitations failed to detect any interaction between Fbxo11 and Smad2. Fbxo11 is known to neddylate p53, a co-factor of pSmad2, but we did not find any evidence of genetic interactions between Jeff and p53 mutants. Nevertheless, p53 levels are substantially reduced in Jeff mice suggesting that Fbxo11 plays a role in stabilizing p53.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11</italic>
###xml 243 250 243 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
Overall, our findings support a model whereby Fbxo11, possibly via stabilization of p53, is required to limit the accumulation of pSmad2 in the nucleus of epithelial cells of palatal shelves, eyelids and airways of the lungs. The finding that Fbxo11 impacts upon TGF-beta signalling has important implications for our understanding of the underlying disease mechanisms of middle ear inflammatory disease.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 101 109 <span type="species:ncbi:9606">children</span>
###xml 218 226 <span type="species:ncbi:9606">children</span>
###xml 525 533 <span type="species:ncbi:9606">children</span>
###xml 583 591 <span type="species:ncbi:9606">children</span>
Otitis media (OM), inflammation of the middle ear, is the most common cause of hearing impairment in children, potentially causing language delays and learning and behavioural disruption [1,2]. A significant number of children with acute OM will go on to develop OM with effusion or chronic OM. The high prevalence of the disease, coupled with its recurrent and chronic nature, accounts for the large number of tympanostomies, the insertion of ventilation tubes or 'grommets' in the tympanic membrane, undertaken in affected children. OM is still the most common cause of surgery in children in the developed world. However, this and other treatments are largely ineffective.
###end p 9
###begin p 10
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Junbo</italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 266 271 <span type="species:ncbi:10090">mouse</span>
###xml 538 544 <span type="species:ncbi:9606">humans</span>
There is evidence from studies of the human population that there is a significant genetic component predisposing to recurrent or chronic OM [3-5], yet little is known about the underlying genetic pathways involved. From a deafness screen as part of the MRC Harwell mouse mutagenesis programme [6] we have identified two novel dominant mutants, Jeff and Junbo, which develop a conductive deafness due to a chronic suppurative OM [7-9]. Both these mutants represent the first models for chronic forms of middle ear inflammatory disease in humans, and both of these mutants have now been cloned [8,9].
###end p 10
###begin p 11
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11</italic>
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 458 481 458 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Caenorhabditis elegans </italic>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1091 1093 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1209 1211 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 458 480 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
###xml 505 510 <span type="species:ncbi:9606">human</span>
###xml 607 612 <span type="species:ncbi:9606">human</span>
The gene underlying the Jeff mutant was identified as Fbxo11, a member of the F-box family [8]. The Jeff mutant carries a non-conservative glutamine to leucine change at amino acid 491. F-box proteins function as part of an SCF (SKP1-cullin-F-box) E3 protein ligase complex, recognizing and binding phosphorylated proteins and promoting their ubiquitination and degradation [10,11]. However, the substrate of Fbxo11 is unknown. It has been demonstrated that Caenorhabditis elegans DRE-1, an orthologue of human FBXO11, and the SKP1-like homologue SKR-1 function as part of an E3 ligase complex, as does its human counterpart [12]. There is also evidence that FBXO11 has arginine methyltransferase activity, catalyzing arginine methylation, but with a structure different from all other known protein arginine methyltransferases (PRMTs) [13]. PRMT activity was not however detected for DRE-1 [12]. Recently it has been demonstrated that FBXO11 can function as a Nedd8-ligase for the tumour suppressor protein p53, promoting the neddylation of p53 and inhibiting its transcriptional activity [14]. p53 is a partner of Smad2 in the activation of multiple transforming growth factor beta (TGF-beta) target genes [15].
###end p 11
###begin p 12
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 323 325 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 326 328 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 396 403 393 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 406 411 <span type="species:ncbi:10090">mouse</span>
We previously reported that mice homozygous for the Jeff mutation die within a few hours of birth [8]. Newborn Jeff homozygotes have cleft palate, facial clefting, impairment of respiratory function and an eyes-open at birth (EOB) phenotype [8]. TGF-beta signalling has been shown to be involved in all of these processes [16-18]. For these reasons it will be important to understand the role of Fbxo11 in mouse developmental processes and in particular the impact of mutations on the TGF-beta signalling pathway.
###end p 12
###begin p 13
###xml 205 207 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 208 210 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 735 737 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 976 978 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
The TGF-beta superfamily is composed of a large number of cytokines involved in a variety of cellular processes such as proliferation, differentiation, epithelial mesenchymal transformation and apoptosis [19,20]. They mediate their effects from membrane to nucleus through combinations of type I and type II serine/threonine kinase receptors (TGFbetaR-I and TGFbetaR-II) and their downstream effectors, Smad proteins. Certain receptor-regulated Smads (R-Smads) become phosphorylated by activated type I receptors and form a heteromeric complex with a common-partner Smad4. Once formed, this R-Smad/Smad4 complex translocates to the nucleus and, in conjunction with other nuclear cofactors, regulates the transcription of target genes [19]. Two different Smad signalling branches have been described. The TGF-beta sub-family ligands TGF-beta, Activins and Nodals, are transduced by Smad2 and Smad3. In contrast, BMP sub-family ligands are transduced by Smad1, Smad5 and Smad8 [19].
###end p 13
###begin p 14
###xml 108 110 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 111 113 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 114 116 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 436 438 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 439 441 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 532 534 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 689 691 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 692 694 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 852 854 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 949 951 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1038 1049 1029 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. elegans </italic>
###xml 1103 1105 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1233 1235 1221 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1038 1048 <span type="species:ncbi:6239">C. elegans</span>
TGF-beta signalling is controlled by many mechanisms, including ubiquitin-mediated proteosomal degradation [19,21,22]. A key component of ubiquitination, the ubiquitin ligase (E3), controls the specificity and timing of Smad ubiquitination. The E3 ubiquitin ligases, Smad ubiquitination-related factor 1 and 2 (Smurf1 and 2), have been identified as regulators of TGF-beta signalling targeting Smad1 for ubiquitination and degradation [23,24]. At higher expression levels, Smurf2 also lowers protein levels of Smad2, but not Smad3 [24]. In addition to regulation of steady-state levels of R-Smads, the ubiquitin-proteosome pathway is also involved in the degradation of activated R-Smads [21,22]. Smurf2 exhibits higher binding affinity to activated Smad2 upon TGF-beta stimulation, and Smurf2 is a candidate E3 ligase for activated Smad2 degradation [25]. Roc1, a component of an SCF complex, interacts and promotes degradation of activated Smad3 [26]. MFB-1, a novel F-box-type ubiquitin ligase, negatively regulates Dauer formation in C. elegans by modulating DAF-7/TGF-beta-like signalling pathway [27]. More recently, Arkadia, a RING-domain E3 ubiquitin ligase, has been shown to interact with and ubiquitinate phospho-Smad2/3 [28]. At the same time, Arkadia enhances transcription, thus coupling turnover of phospho-Smad2/3 to activity.
###end p 14
###begin p 15
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 144 151 144 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 433 438 427 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 603 608 597 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 612 618 606 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2 </italic>
###xml 645 650 639 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 749 756 743 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 760 765 754 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2</italic>
###xml 910 916 904 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11</italic>
###xml 1103 1110 1097 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 1268 1273 1259 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 576 580 <span type="species:ncbi:10090">Mice</span>
We have set out to explore the role of Fbxo11 in development and to relate the Jeff homozygous mutant phenotype to the underlying mechanisms of Fbxo11 function. Given the findings of a palatal and EOB phenotype in Jeff mice and the role of TGF-beta signalling in these processes, we have focused our studies on salient members of the TGF-beta family signalling pathway and demonstrated that pSmad2 is upregulated in the epithelia of Jeff homozygotes. Moreover, we have utilized compound mutants to assess genetic interactions and throw light on the genetic pathways affected. Mice heterozygous for both Jeff and Smad2 mutations recapitulate the Jeff homozygote phenotype in the palate and lungs. However, we failed to detect any interaction between Fbxo11 and Smad2, suggesting they are indirect partners in the development of these tissues. Our observations support a model whereby in palate, eyelid and lung Fbxo11-dependent modification is required to limit the accumulation of pSmad2 in the nucleus of epithelial cells of palatal shelves, eyelids and airways of the lungs. Overall, we conclude that Fbxo11 is involved with the regulation of TGF-beta signalling, a finding that has implications for the chronic middle ear inflammatory phenotype that is observed in Jeff heterozygotes.
###end p 15
###begin title 16
Results
###end title 16
###begin p 17
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 304 309 295 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
Jeff homozygote mutant mice develop a variety of epithelial developmental abnormalities, including palatal and EOB phenotypes. We used immunohistochemistry (IHC) to study protein expression and localization of members of the TGF-beta signalling pathway (TGFbeta-3, TGFbetaR-I, Smad2, Smad3 and Smad4) in Jeff mutants in both palatal and eye tissues at relevant developmental stages. Given the apparent involvement of Fbxo11 in epithelial development, we also investigated the expression of these TGF-beta signalling pathway members in lung development.
###end p 17
###begin title 18
Palatal expression in Jeff mutants
###end title 18
###begin p 19
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 237 239 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 418 423 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 424 429 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 451 452 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 778 780 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 799 805 790 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1008 1010 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 1026 1032 1017 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1252 1254 1243 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1360 1366 1351 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1497 1503 1479 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1573 1575 1555 1557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 1596 1597 1578 1579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1733 1735 1715 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 805 809 <span type="species:ncbi:10090">mice</span>
###xml 1131 1135 <span type="species:ncbi:10090">mice</span>
###xml 1246 1250 <span type="species:ncbi:10090">mice</span>
###xml 1366 1370 <span type="species:ncbi:10090">mice</span>
###xml 1395 1399 <span type="species:ncbi:10090">mice</span>
###xml 1503 1507 <span type="species:ncbi:10090">mice</span>
Jeff homozygote palatal shelves start to grow and lift on time, but they fail to fuse at the right developmental stage (Figure 1a) and homozygote mice are born with cleft palate (Figure 1b). This is reminiscent of TGF-beta3 mutant mice [29]. To characterize the distribution pattern of TGF-beta ligands, TGF-beta receptors and Smads in the developing palates, we examined embryonic heads from wild-type and homozygote Jeff (Jf/Jf) mice by IHC (Figure 2). The result revealed one major difference in the pattern and localization of pSmad2. In wild types at embryonic day 15.5 (E15.5), as the midline epithelial seam was disrupted and medial edge epithelium (MEE) disappeared, pSmad2 was largely confined to the oral/nasal triangle area as a nuclear and cytoplasmic stain (Figure 2b). In contrast, in Jf/Jf mice at E15.5 an increased number of epithelial cells are positive for pSmad2 in the palatal shelves concentrated to the tip of the palatal epithelium and the oral/nasal palatal epithelial cells (Figure 2b). Moreover, in Jf/Jf palates at E15.5 pSmad2 was present as a nuclear stain in the majority of the cells. In homozygote mice 57% of epithelial cells in the palate showed a nuclear localization of pSmad2, compared with 27% in wild-type mice (P = 0.000255). There was a commensurate significant decrease in cells showing a cytoplasmic localization in Jf/Jf mice compared with wild-type mice. TGF-beta3, TGFbetaR-I, TGFbetaR-II, Smad2, Smad4, Smurf2 and also Fbox11, in both wild-type and Jf/Jf mice, were localized to the cytoplasm of the epithelial cells (Figure 2a and Additional file 1). There was no difference in the distribution of activated Smad2 in wild-type and homozygote palates before the fusion (E14.5) (Figure 2b).
###end p 19
###begin p 20
###xml 0 22 0 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cleft palate phenotype</bold>
###xml 24 25 24 25 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 216 217 215 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 338 343 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 296 301 <span type="species:ncbi:10090">mouse</span>
###xml 353 358 <span type="species:ncbi:10090">mouse</span>
Cleft palate phenotype. a. Coronal sections through the palate of E14.5 (before the fusion) and E15.5 (after the fusion) wild-type (WT) and homozygote (Jf/Jf) embryos, haematoxylin-eosin stained. Scale bars 200 mum. b. Cross-sections of heads showing secondary palate of a wild-type (WT) newborn mouse with fused palate and a homozygote (Jf/Jf) newborn mouse with a cleft (arrow).
###end p 20
###begin p 21
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunolocalization in palate tissue</bold>
###xml 37 38 37 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 347 352 340 345 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graph</bold>
###xml 465 466 458 459 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 585 590 578 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 701 706 693 698 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graph</bold>
###xml 860 861 852 853 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 939 944 931 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 1055 1060 1046 1051 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graph</bold>
###xml 1185 1186 1176 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1227 1228 1218 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
Immunolocalization in palate tissue. a. Coronal sections through the palate of E15.5 wild-type (WT) and homozygote (Jf/Jf) embryos, immunohistochemically stained with antibodies against Fbox11, TGF-beta3, TGFbetaR-I, Smad2, and Smad4. Scale bar 50 mum. Medial edge epithelium (mee), nasal palatal epithelium (ne) and oral palatal epithelium (oe). Graph: comparison of the percentage of epithelial cells positive for Smad2 in E15.5 wild-type and homozygote palates. b. Coronal sections through the palate of E14.5 (before fusion) and E15.5 (after fusion) wild-type (WT) and homozygote (Jf/Jf) embryos, immunohistochemically stained with pSmad2 antibody. Scale bar 50 mum. Medial edge epithelium (mee). Graph: comparison of the percentage of epithelial cells positive for nuclear and cytoplasmic localization of pSmad2 in E15.5 wild-type and homozygote palates. c. Coronal sections through the palate of E15.5 wild-type (WT) and homozygote (Jf/Jf) embryos, immunohistochemically stained with antibodies against Ki67 and cleaved caspase-3. Scale bar 50 mum. Graph: comparison of the percentage of epithelial cells positive for cleaved caspase-3 in E15.5 wild-type and homozygote palates. P-values were determined using two-tailed T-test.
###end p 21
###begin p 22
###xml 82 84 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 291 297 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 340 342 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 644 650 641 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 665 667 662 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 687 689 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
TGF-beta3 has been implicated to inhibit MEE proliferation during palatal fusion [30]. We used Ki67 as a marker for proliferation and examined E14.5 (data not shown) and E15.5 palates using IHC. We were unable to detect any significant differences in staining patterns along the MEE between Jf/Jf palatal tissues and wild-type mice (Figure 2c). There are three cellular fates for the MEE: epithelial-mesenchymal transformation, migration and programmed cell death. We used a cleaved caspase-3 antibody to compare cells undergoing apoptosis in E15.5 wild-type and homozygote palates. The results indicate that there are fewer apoptotic cells in Jf/Jf E15.5 palates (P = 0.017547) (Figure 2c), most likely reflecting the absence of shelf fusion that is followed by MEE disintegration.
###end p 22
###begin title 23
Eyelid expression in Jeff mutants
###end title 23
###begin p 24
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 278 284 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 504 510 504 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 865 867 865 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 879 881 879 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 995 1001 995 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 1167 1173 1158 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1201 1203 1192 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 1224 1225 1215 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1318 1320 1309 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 1341 1342 1332 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1441 1447 1432 1438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1969 1971 1960 1962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
###xml 510 514 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 1537 1541 <span type="species:ncbi:10090">mice</span>
###xml 1718 1722 <span type="species:ncbi:10090">mice</span>
Jeff homozygous mutant eyelids start to grow on time, but fail to fuse at the correct developmental stage and the mice have an EOB phenotype (Figures 3a and 3b). We have applied the same panel of antibodies used on the palates to sections of E16 eyelids from both wild-type and Jf/Jf mice. These studies revealed similar results to those observed on palates. The majority of localization of pSmad2 in wild-type E16 eyelids was cytoplasmic. The staining was confined to the epidermis only (Figure 4b). In Jf/Jf mice more cells are positive for pSmad2 than in wild type. Moreover, pSmad2 was present as a nuclear stain in the majority of the cells of the epidermis. In homozygote mice 66% of epithelial cells in the upper eyelids and 56% of epithelial cells in the lower eyelids showed nuclear localization of pSmad2, compared with 11% and 17% in the wild-type mice (P = 0.000333, P = 0.0000473) (Figure 4b). Staining was also observed in the basal layer and also in some cells from the dermis of Jf/Jf eyelids (Figure 4b). The expression pattern of TGF-beta3, TGFbetaR-I, TGFbetaR-II, Smad2, Smad3, Smad4, Smurf2 and Fbox11 at the same stage E16 in both wild-type and Jf/Jf eyelids was similar (Figure 4a and Additional file 1). They were all localized to the cytoplasm of the epithelial cells of the epidermis (Figure 4a and Additional file 1). We examined also the distribution of pSmad2 at E15.5, before the closure. In both wild-type and Jf/Jf eyelids activated Smad2 was detectable as nuclear and cytoplasmic staining. In homozygote mice 27% of epithelial cells in the upper eyelids and 19% of epithelial cells in the lower eyelids showed nuclear localization of pSmad2, compared with 41% and 32% in the wild-type mice. Eleven per cent of epithelial cells in the homozygote upper eyelids and 9% of epithelial cells in the homozygote lower eyelids showed cytoplasmic localization of pSmad2, compared with 12% and 9% in the wild-type eyelids (data not shown) (Figure 4b).
###end p 24
###begin p 25
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Eyelid open phenotype</bold>
###xml 23 24 23 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 205 206 204 205 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 258 263 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 251 256 <span type="species:ncbi:10090">mouse</span>
Eyelid open phenotype. a. Haematoxylin-eosin stained coronal sections through the eyes of E15.5 (before fusion) and E16 (after fusion) in wild-type (WT) and homozygote (Jf/Jf) embryos. Scale bars 200 mum. b. Failure of eyelids closure in a homozygote mouse (Jf/Jf) at birth (arrow).
###end p 25
###begin p 26
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunolocalization in eyelid tissue</bold>
###xml 37 38 37 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 254 259 247 252 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graph</bold>
###xml 361 362 354 355 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 480 485 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 594 599 586 591 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graph</bold>
###xml 743 744 735 736 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 821 826 813 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 907 912 898 903 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graph</bold>
###xml 1034 1035 1025 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1076 1077 1067 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
Immunolocalization in eyelid tissue. a. Coronal sections through the eye of E16 wild-type (WT) and homozygote (Jf/Jf) embryos immunohistochemically stained with antibodies against Fbox11, TGF-beta3, TGFbetaR-I, Smad3, Smad2 and Smad4. Scale bar 200 mum. Graph: comparison of the percentage of epithelial cells positive for Smad2 in E16 upper and lower eyelids. b. Coronal sections through the eyes of E15.5 (before fusion) and E16 (after fusion) in wild-type (WT) and homozygote (Jf/Jf) embryos stained with pSmad2 antibody (scale bar 200 mum). Epidermis (ep), basal cells (bc) and dermis (d). Graph: comparison of the percentage of epithelial cells with positive nuclear and cytoplasmic localization of pSmad2 in E16 upper and lower eyelids. c. Coronal sections through the eyes of E16 in wild-type (WT) and homozygote (Jf/Jf) embryos stained with Ki67 and cleaved caspase-3 antibodies. Scale bar 200 mum. Graph: comparison of the percentage of epithelial cell positive for Ki67 and cleaved caspase-3 in E16 upper and lower eyelids. P-values were determined using two-tailed T-test comparing each homozygote eyelid with the wild type.
###end p 26
###begin p 27
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 245 247 245 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 276 278 276 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 524 530 524 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 627 633 627 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
To compare apoptotic cells in wild-type and Jf/Jf junctional zones of the eyelids we again employed cleaved caspase-3 antibody. As with our palate studies, we observed fewer cells positive for cleaved caspase-3 in Jf/Jf E16 eyelids (Figure 4c) (P = 0.008006 for the upper and P = 0.0008781 for the lower eyelids). The process of eyelid closure coordinates both cell proliferation and migration. We used Ki67 as a marker for proliferation, comparing the number of Ki67 positive cells in the epidermis of E16 of wild-type and Jf/Jf eyelids. We saw no significant differences, indicating that proliferation is not affected in the Jf/Jf eyelids (Figure 4c).
###end p 27
###begin title 28
###xml 24 28 <span type="species:ncbi:10090">mice</span>
Lung phenotype of Jf/Jf mice
###end title 28
###begin p 29
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 318 324 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 369 375 366 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 492 494 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 581 587 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 888 894 885 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 895 897 892 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 920 922 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 1023 1029 1020 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1143 1145 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 1217 1223 1214 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 1428 1430 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 1029 1033 <span type="species:ncbi:10090">mice</span>
Newborn Jf/Jf mice die soon after birth and gasp for air. Moreover, lung development, like palate and eyelid development, involves growth of epithelial tissue and, in addition, the TGF-beta signalling pathway is known to be important in this process. We therefore investigated whether lung development was affected in Jf/Jf embryos. Examination of pSmad2 expression in Jf/Jf lungs revealed a similar picture to that which we had previously observed in both the eyelids and the palate (Figure 5a). The localization of pSmad2 in E15.5 wild-type lungs was cytoplasmic and nuclear. In Jf/Jf lungs the number of positive cells was significantly increased and the localization was exclusively nuclear. The increase in pSmad2-positive cells was particularly striking in proximal airways where 19% of wild-type proximal airway cells were positive for nuclear pSmad2, and this increased to 79% in Jf/Jf (P = 0.00005); see Figure 5a. In contrast, no significant difference was seen in the localization of Smad2 between wild-type and Jf/Jf mice. The accumulation of pSmad2 in the nucleus of whole lungs was also examined by Western blot analysis (Figure 5b) and clearly demonstrated a marked increase in nuclear localization in Jf/Jf homozygotes, consistent with our observations from immunostaining. Immunostaining of lungs with a marker for proliferation (Ki67) showed no difference between wild-type and homozygous mutant lungs (Figure 5a).
###end p 29
###begin p 30
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lung phenotype</bold>
###xml 16 17 16 17 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 225 231 223 229 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graphs</bold>
###xml 328 329 326 327 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 423 425 421 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf</italic>
###xml 445 450 443 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 608 613 606 611 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graph</bold>
###xml 681 682 679 680 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 768 773 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 802 807 799 804 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graph</bold>
###xml 874 876 871 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 879 881 875 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 948 949 944 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 990 991 986 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
Lung phenotype. a. Sections through the lungs of E15.5 wild-type (WT) and homozygote (Jf/Jf) embryos, immunohistochemically stained with antibodies against Ki67, Smad2 and pSmad2 (scale bars 200 mum and 20 mum as indicated). Graphs: comparison of the percentage of cells positive for Ki67, Smad2 and pSmad2 in proximal airways. b. Western blot analysis: cytoplasmic and nuclear fractions from wild-type (wt), heterozygote (Jf/+) and homozygote (Jf/Jf) whole E15.5 lungs. Equal amounts of protein were subjected to tris-acetate PAGE, transferred and probed with pSmad2 and actin antibody for loading control. Graph: comparison of the normalised pSmad2 signals in the two fractions. c. Haematoxylin-eosin stained sections through new born wild-type (WT) and homozygote (Jf/Jf) lungs. Scale bars 200 mum. Graph: comparison of the number of airways for three regions of 5.3 x 106 mum2 taken at random and the width of 3 x 30 airways for each genotype. P-values were determined using two-tailed T-test.
###end p 30
###begin p 31
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
In newborn Jf/Jf mice the lungs are severely affected. We observed thickened interstitial mesenchyme and fewer, smaller alveoli than in wild-type littermates. On average, the airway width in homozygous mutants was significantly smaller than wild-type tissue (Figure 5c). Moreover, quantification of the number of airways indicated a very significant reduction in homozygous mutants (Figure 5c). The mutant mice die soon after birth, probably as a consequence of their lung defect. Cleft palate does not lead to death this early. Immunostaining of lungs with a marker for Clara cells in the proximal airways (CC10) showed no difference in the number or structure of proximal airways between wild-type and homozygous mutant lungs (data not shown).
###end p 31
###begin title 32
Genetic interaction of Fbxo11 and Smad2
###end title 32
###begin p 33
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 207 213 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2 </italic>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbox11</italic>
###xml 260 266 260 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2 </italic>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 339 351 339 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+</italic>
###xml 466 468 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 479 481 477 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 526 539 524 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+ </italic>
###xml 674 686 672 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+</italic>
###xml 688 692 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+</italic>
###xml 694 702 692 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2/+ </italic>
###xml 731 744 729 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+ </italic>
###xml 853 859 851 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 906 907 904 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 932 945 930 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+ </italic>
###xml 1050 1051 1048 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 744 748 <span type="species:ncbi:10090">mice</span>
###xml 945 949 <span type="species:ncbi:10090">mice</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
It appears that the Jeff mutation results in an increased expression as well as increased nuclear localization of pSmad2 in epithelial tissues. We therefore decided to examine genetically the interaction of Smad2 and Fbox11. We crossed mice heterozygous for a Smad2 null mutation to Jeff heterozygotes to produce double heterozygous mice: Jf/+ Smad2/+. Double heterozygotes comprised 21.6% (57/264) of mice from this cross, significantly different from expected (chi2 = 8.54546, P = 0.035986, df = 3). However, 66% (36/57) of Jf/+ Smad2/+ mice died soon after birth due to respiratory problems. We performed an extensive histological examination of the palates and lungs of Jf/+ Smad2/+, Jf/+, Smad2/+ and wild-type mice. Notably, Jf/+ Smad2/+ mice with early postnatal mortality demonstrated cleft palate and poorly developed lungs, recapitulating the Jf/Jf phenotype of smaller and fewer airways (Figure 6). A proportion (34%) of Jf/+ Smad2/+ mice survives. These mice do not have cleft palate and appear to display a milder lung phenotype (Figure 6). The surviving double heterozygous mice are also smaller than their wild-type and single heterozygous littermates.
###end p 33
###begin p 34
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lung phenotype of double heterozygotes</bold>
###xml 40 41 40 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 163 165 163 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf</italic>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2</italic>
###xml 210 212 210 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf</italic>
###xml 319 320 318 319 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 395 397 394 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 400 402 398 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 462 463 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 504 505 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
Lung phenotype of double heterozygotes. a. Sections through the lungs of newborn wild-type (+/+ +/+), heterozygote for Smad2 (+/+ Smad2/+), heterozygote for Jeff (Jf/+ +/+) and two double heterozygote (Smad2/+ Jf/+) mice: with and without cleft palate. The sections were haematoxylin-eosin stained. Scale bars 200 mum. b. Graphic comparison of the number of airways for three regions of 5.3 x 106 mum2 taken at random and the width of airways for each genotype. P-values were determined using two-tailed T-test comparing each with the wild type.
###end p 34
###begin title 35
Genetic interaction of Fbxo11 and p53
###end title 35
###begin p 36
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 275 280 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ </italic>
###xml 357 367 357 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ p53/+</italic>
###xml 453 455 451 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 466 468 464 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 502 513 500 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ p53/+ </italic>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
Recently, it has been shown that Fbxo11 acts as a Nedd8-ligase to p53. Neddylation of p53 by Fbxo11 leads to a reduction in transcriptional activity [14]. Given these findings and that p53 is a co-factor of pSmad2, we examined the genetic interaction between p53 and Fbxo11. Jf/+ mice and p53 homozygotes were intercrossed to produce double heterozygotes - Jf/+ p53/+. Compound heterozygotes comprised 44.9% (31/69) of the mice born from this cross (chi2 = 0.72464, P = 0.399397, df = 1). However, all Jf/+ p53/+ mice appeared phenotypically normal (data not shown).
###end p 36
###begin title 37
Biochemical interactions of Fbxo11, Smad2 and p53
###end title 37
###begin p 38
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
We explored further the genetic interaction between Fbxo11 and Smad2 by performing immunoprecipitations to test whether these two proteins interact. We used a cross-linking agent to improve the likelihood of detecting the interactions. However, immunoprecipitations with Smad2 antibodies failed to reveal any interaction with Fbxo11 (Figure 7a), suggesting that Smad2 or pSmad2 is not a substrate for ubiquitination by Fbxo11. However, Smad2 did immunoprecipitate p53, confirming the known interaction between these two proteins (Figure 7a).
###end p 38
###begin p 39
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunoprecipitation and Western blot analysis</bold>
###xml 47 48 47 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 248 249 248 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 510 511 510 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
Immunoprecipitation and Western blot analysis. a. Immunoprecipitation: lung extract from E15.5 wild-type embryos was used for immunoprecipitation using Smad2 and p53 antibodies. The Western blots were probed with pSmad2, Fbox11 and p53 antibodies. b. Western blot analysis: protein lysates from wild-type, heterozygote and homozygote E15.5 palates. Equal amounts of protein were subjected to tris-acetate PAGE, transferred and probed with pSmad2, Fbox11, p53 antibodies and actin antibody for loading control. c. Graphical representation of p53 levels normalized against actin in wild-type, heterozygote and homozygote E15.5 palates, showing approximately threefold reduction of p53 in homozygote palate compared with wild type.
###end p 39
###begin p 40
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7b</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7c</xref>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
We also undertook immunoprecipitations with p53 (Figure 7a) using lung tissue. We also failed to detect any interaction between Fbxo11 and p53, despite the reported neddylation of p53 by Fbxo11. Intriguingly, we find that in Jeff homozygote mice p53 is expressed at very low levels (Figure 7b and 7c). The heterozygote appears to display intermediate levels. These results suggest that Fbxo11 plays a role in stabilising p53.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
We previously identified a mutation in Fbxo11 in the Jeff mutant mice [8]. Jeff heterozygote mice develop chronic OM [7] and Jeff homozygotes demonstrate perinatal lethality, cleft palate and an EOB phenotype [8]. We investigated the impact of the Jeff mutation on the TGF-beta signalling pathway, paying particular attention to those members of the pathway that have a role in epithelial development.
###end p 42
###begin p 43
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 468 470 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 605 607 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 608 610 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 624 626 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 729 731 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 895 897 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1098 1100 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1357 1359 1333 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1487 1489 1460 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 310 316 <span type="species:ncbi:9606">humans</span>
###xml 318 324 <span type="species:ncbi:10090">Murine</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 616 622 <span type="species:ncbi:9606">humans</span>
In mammalian development the formation of the palate is a multi-step process, involving palatal shelf growth and elevation above the tongue, followed by fusion of the shelves and the disappearance of the MEE [31]. Defects in any of these steps can lead to cleft palate, one of the most common birth defects in humans. Murine palatogenesis takes place between E11.5 and E15.5 [31]. All TGF-beta ligands are known to be expressed at that stage in the developing palate [32]. Amongst them, TGF-beta3 is likely to be the most important in palatogenesis since mutation of the gene causes cleft palate in mice [29,33] and humans [34]. In palate cultures from these mutant embryos, the fusion defect is rescued by endogenous TGF-beta3 [35]. It has been demonstrated that TGF-beta3 selectively regulates the disappearance of MEE during palatal fusion: TGF-beta3 disintegrates the MEE basement membrane [36]. Studies on the mechanism for MEE disappearance during palatal fusion suggests a role of TGF-beta3 as an inducer of apoptosis - cell death in TGF-beta3 null palates is reduced at the time of fusion [37]. Smad2 and Smad3, mediators of TGF-beta signalling, are expressed in the MEE cells, but only Smad2 is phosphorylated during palatal fusion. Smad2 phosphorylation is temporo-spatially restricted to the MEE and correlates with the disappearance of the MEE [30]. TGF-beta3 is required for phosphorylation of Smad2 in the MEE and the inhibition of MEE proliferation during palatal fusion [30].
###end p 43
###begin p 44
###xml 162 168 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 379 385 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf </italic>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
Our studies using IHC to co-localize the TGF-beta3 ligand, TGF-beta receptors and Smads in developing palates revealed one major difference between wild-type and Jf/Jf mice. At E15.5 more epithelia cells are positive for pSmad2 in the homozygote palatal shelves than in the wild type. Moreover, we found that there was a substantial increase in nuclear localization of pSmad2 in Jf/Jf mice. This might suggest that the turnover of pSmad2 is stalled and pSmad2 accumulates in the nucleus, with consequent effects for TGF-beta signalling in the epithelia.
###end p 44
###begin p 45
###xml 83 85 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 116 118 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 239 244 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 371 376 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 451 457 448 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11</italic>
TGF-beta3 plays a role as an inhibitor of MEE proliferation during palatal fusion [30] and an inducer of apoptosis [37]. Using Ki67 as a marker for proliferation we did not observe increased proliferation in E14.5 and E15.5 palates of the Jeff homozygote MEE. However, we also stained for apoptotic cells using a caspase-3 antibody and found many fewer positive cells in Jeff homozygote E15.5 palates. It appears that in the presence of a mutation in Fbxo11, palatal fusion is inhibited and MEE cells are not able to progress to epithelial programmed cell death or epithelial-mesenchymal transformation.
###end p 45
###begin p 46
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 945 947 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 999 1001 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1110 1112 1101 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1113 1115 1104 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1247 1249 1235 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
###xml 723 728 <span type="species:ncbi:10090">Mouse</span>
###xml 993 997 <span type="species:ncbi:10090">mice</span>
The palatal shelves fusion is a permanent fusion, such as the fusion of the neural tube. During mammalian development some temporary fusions also occur for example, eyelid fusion, fusion of the digits and fusion of the pinnae of the ears to the scalp. The disjunction of the temporary fusions takes place after birth [38]. The eyelids develop at approximately the same time as the palatal shelves. They start to form at about E11.5, grow across the eye from E14 to E16 and, as the fusion progresses, the diminishing gap fills with a profusion of rounded cells that are extruded, flattened, and sloughed off from the area of completed fusion [38,39]. Failure of the eyelids to grow and fuse in mice leads to the EOB defect. Mouse knockout studies have identified several signalling molecules involved in the control of embryonic eyelid closure and some of them are from the TGF-beta family. Mutation in activin betaB results in an EOB phenotype [40] similar to that observed in MEKK1-deficient mice [41]. TGF-beta/activin signalling via the MEKK1-mediated JNK pathway is one pathway controlling eyelid closure [17,42]. MEKK1 is not required however for the classical TGF-beta/activin pathway, which involves nuclear translocation of Smad proteins [17].
###end p 46
###begin p 47
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 887 892 881 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 1153 1158 1147 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Normally in mouse development, the eyelid fusion is complete by E16, but the eyelids of Jeff homozygote mice remain wide apart. The eyelids start to form the leading edge of the developing margins, but the leading edge is not extended and the eyelids do not reach each other. We applied the same panel of antibodies, employed on the palates, on sections of E16 eyelids. The expression pattern of TGF-beta3 and the signalling receptor TGFbetaR-I are consistent with localization observed in the cytoplasm of the cells of the epidermis of both the developing wild-type and mutant eyelids. The distribution of non-activated Smads is also similar, but with pSmad2 there is a clear difference between the wild-type and homozygote eyelids. Activated Smad2 was present as a nuclear stain in the majority of the cells of the epidermis, the basal layer and also some cells from the dermis of the Jeff homozygote eyelids. In contrast, in wild-type eyelids the pSmad2 is localized in the cytoplasm of the epidermis. The difference is also time specific. At E15.5 before eyelid fusion the pattern and the localization of activated Smad2 is similar in wild type and Jf/Jf. These findings mirror and are consistent with the expression changes observed in the palate.
###end p 47
###begin p 48
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
In the developing eyelid, as with the palate, we also studied proliferation and apoptosis in the Jeff homozygote. Using Ki67 as a marker for proliferation, we found that there was little difference between wild-type and mutant homozygotes in the number or distribution of cells stained. However, we found significantly lower staining with caspase-3 in the Jeff homozygote, indicating reduced rates of apoptosis. It would appear that, as with the palate, the absence of epithelial fusion prevents the transition to epithelial programmed cell death.
###end p 48
###begin p 49
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 154 159 <span type="species:ncbi:10090">mouse</span>
We show here that, in addition to palatal and eyelid development defects, the development of the lung in Jeff homozygotes is severely compromised. In the mouse, early lung development begins at about E9.5 with the formation of the paired lung buds and continues through the pseudoglandular phase at E9.5-16.5 when the bronchial and respiratory tree develops, and the canalicular phase E16.5-17.5 when vascularization occurs. During late lung development at E17.5-P4 the distal airways form saccular units (saccular stage) and the secondary septae divides these units during the alveolar stage at P5-28 [43,44].
###end p 49
###begin p 50
###xml 245 247 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 375 377 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 496 498 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 694 696 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1020 1022 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 172 177 <span type="species:ncbi:10090">mouse</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 897 901 <span type="species:ncbi:10090">mice</span>
Several studies have implicated TGF-beta signalling in early lung development. Immunohistochemical studies on localization of the three TGF-beta isoforms in the developing mouse embryo suggest that they play an important role in lung formation [18]. TGF-beta signalling is implicated in the negative regulation of lung growth and development during early lung organogenesis [45]. Recent expression data also indicates that active TGF-beta signalling is required for normal late lung development [46]. Gene-targeting studies also demonstrate the involvement of the TGF-beta family in early and late lung morphogenesis. TGF-beta3 null newborn mice have under-developed and poorly inflated lungs [33]. The developmental delay is detectable as early as day E12.5, which implicates a role of TGF-beta3 in early lung development. Retarded lung alveolarization and subsequent emphysema in Smad3 knockout mice, on the other hand, suggests a role for the TGF-beta/Smad3 pathway in postnatal lung growth and emphysema prevention [47]. As the TGF-beta family is involved in lung morphogenesis and reflecting the changes in pSmad2 expression and localization in the palate and eyelid, we have explored pSmad2 in the developing lung. Again, we find a significant increase in the expression of pSmad2. Most notably, there is a very marked increase in localization of pSmad2 to the nuclei of epithelial cells lining the airways.
###end p 50
###begin p 51
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 164 177 164 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+ </italic>
###xml 229 242 229 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+ </italic>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 394 407 394 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+ </italic>
###xml 474 487 474 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+ </italic>
###xml 614 627 614 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ Smad2/+ </italic>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ </italic>
###xml 720 727 720 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 1008 1015 1008 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 1019 1025 1019 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2 </italic>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
Given the effects of the Fbxo11 mutation on pSmad2 in a variety of tissues, we decided to examine genetically the interaction between these two genes and generated Jf/+ Smad2/+ compound heterozygotes. Intriguingly, we found that Jf/+ Smad2/+ mice recapitulated many of the features of Jeff homozygotes, including the cleft palate, lung phenotype and post-natal mortality. The phenotypes of the Jf/+ Smad2/+ compound heterozygote are not fully penetrant. Around one-third of Jf/+ Smad2/+ mice survive but are much smaller than wild-type or single-mutant littermates. The developmental abnormalities observed in the Jf/+ Smad2/+ mice contrasts with the normal phenotype seen in Jf/+ mice and underlines the effects of the Fbxo11 mutation on pSmad2. It would appear that a complete absence of Fbxo11 function, with consequent effects on pSmad2 expression and localization, can lead to the epithelial developmental defects that we have observed. Alternatively, compromising levels of gene expression at both the Fbxo11 and Smad2 loci leads to the same phenotype.
###end p 51
###begin p 52
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 456 467 456 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/+ p53/+ </italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
Despite the effects of the Fbxo11 mutation, and the genetic interaction observed between Fbxo11 and Smad2, we failed to observe any biochemical interaction between Fbxo11 and Smad2. As expected we were able to demonstrate the known interaction between Smad2 and p53. It has been reported that Fbxo11 neddylates p53, inhibiting its transcriptional activity [14]. However, immunoprecipitations did not reveal an interaction in the tissues we tested. Indeed, Jf/+ p53/+ compound heterozygotes did not show any developmental phenotypes. Nevertheless, we found that Jeff homozygotes have markedly reduced levels of p53 and heterozygotes appeared to have intermediate levels. It appears that Fbxo11 is required for stabilisation of p53.
###end p 52
###begin p 53
###xml 76 78 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 301 309 292 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 342 344 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 402 409 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 680 685 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 888 890 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1010 1017 992 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
p53 is required for TGF-beta responses through its interactions with Smads [15]. p53-deficient mammalian cells demonstrate impaired responses to TGF-beta signals. Most importantly, p53 and Smad2 cooperated synergistically at target promoters for TGF-beta signalling, and indeed they directly interact in vivo in a TGF-beta-dependent fashion [15]. We propose that in the Jeff homozygous mutant, loss of Fbxo11 function leads to destabilisation of p53 by an unknown mechanism. It is possible, given the synergistic interaction between p53 and Smad2, that the loss of p53 at transcriptional targets leads to stalling and accumulation of pSmad2 in the nuclei of epithelial tissues of Jeff homozygotes. Mutant p53 leads to attenuation of TGF-beta1 signalling including a reduction in Smad2/3 phosphorylation, inhibition of Smad2/Smad4 complex formation and Smad4 translocation to the nucleus [48]. Overall, given the interaction between p53 and TGF-beta signalling pathways, it seems likely that the effects of the Fbxo11 mutation on TGF-beta signalling may be mediated through effects on p53.
###end p 53
###begin p 54
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 472 477 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff </italic>
###xml 612 619 612 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fbxo11 </italic>
###xml 925 927 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 204 209 <span type="species:ncbi:10090">mouse</span>
###xml 712 717 <span type="species:ncbi:9606">human</span>
###xml 774 779 <span type="species:ncbi:9606">human</span>
###xml 881 886 <span type="species:ncbi:9606">human</span>
Chronic and recurrent OM in the human population is known to have a very significant genetic component, yet little is known about the underlying genes or pathways involved. Moreover, although a number of mouse strains are available that show OM, they are complicated by poor penetrance or the complex syndromic nature of the disease. Jeff heterozygotes develop a highly penetrant chronic suppurative OM in the absence of any other significant pathology [7,8] and thus the Jeff mutant represents a powerful model for studying the genetic and pathophysiological bases of chronic/recurrent OM. The discovery of the Fbxo11 gene underlying the Jeff mutant identified an important candidate for the study of OM in the human population. Indeed, initial studies with FBXO11 SNPs in human OM families have demonstrated nominal evidence of association, indicating the genetic involvement of human FBXO11 with chronic and recurrent OM [49].
###end p 54
###begin title 55
Conclusion
###end title 55
###begin p 56
###xml 267 273 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Junbo </italic>
###xml 274 275 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 237 242 <span type="species:ncbi:10090">mouse</span>
###xml 572 577 <span type="species:ncbi:9606">human</span>
The studies reported here support a role for Fbxo11 in TGF-beta signalling and suggest that perturbations in this pathway may underlie chronic inflammation in the middle ear. This is particularly pertinent given the studies of a similar mouse mutant with chronic OM, Junbo [9], caused by a mutation in the transcription factor Evi1 which is a co-repressor of Smad3. Overall, there is increasing evidence that defects in TGF-beta signalling or associated pathways may underlie the development of chronic OM, and genes in these pathways represent good candidates for future human association studies.
###end p 56
###begin title 57
Methods
###end title 57
###begin title 58
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 58
###begin p 59
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jeff</italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad2 </italic>
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
The Jeff, Smad2 and p53 colonies were maintained on the C57BL/6J background and genotyped as previously described [8,50,51].
###end p 59
###begin title 60
Histology
###end title 60
###begin p 61
###xml 188 192 <span type="species:ncbi:10090">mice</span>
The embryonic (E14.5-E16) and newborn heads and bodies were fixed in 10% buffered formaldehyde, decalcified and embedded in paraffin following routine procedures. The lungs of the newborn mice were inflated with 10% buffered formaldehyde, fixed and paraffin-embedded. Three-micrometer-thick sections were obtained, de-paraffinized in xylene substitute and rehydrated via a graded ethanol. For morphological observations, sections were stained with haematoxylin and eosin.
###end p 61
###begin title 62
Antibodies
###end title 62
###begin p 63
###xml 619 620 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 32 38 <span type="species:ncbi:9986">rabbit</span>
###xml 95 101 <span type="species:ncbi:9986">rabbit</span>
###xml 160 166 <span type="species:ncbi:9986">rabbit</span>
###xml 208 212 <span type="species:ncbi:9925">goat</span>
###xml 266 272 <span type="species:ncbi:9986">rabbit</span>
###xml 308 314 <span type="species:ncbi:9986">rabbit</span>
###xml 350 356 <span type="species:ncbi:9986">rabbit</span>
###xml 458 464 <span type="species:ncbi:9986">rabbit</span>
###xml 501 507 <span type="species:ncbi:9986">rabbit</span>
###xml 570 576 <span type="species:ncbi:9986">rabbit</span>
###xml 623 629 <span type="species:ncbi:9986">rabbit</span>
###xml 700 705 <span type="species:ncbi:10090">mouse</span>
###xml 734 740 <span type="species:ncbi:9986">rabbit</span>
###xml 788 794 <span type="species:ncbi:9986">rabbit</span>
The antibodies were as follows: rabbit polyclonal TGF-beta3 (sc-90, Santa Cruz Biotechnology), rabbit polyclonal TGFbetaR-I (sc-398, Santa Cruz Biotechnology), rabbit polyclonal TGFbetaR-II (ab28382, Abcam), goat polyclonal Smad2 (sc-6200 Santa Cruz Biotechnology), rabbit polyclonal Smad3 (06-920 Upstate), rabbit polyclonal Smad4 (06-693 Upstate), rabbit polyclonal anti-phospho Smad2 (Ser 465/467) (AB3849 Chemicon International and 3101 Cell Signaling), rabbit polyclonal SMURF2 (07-249 Upstate), rabbit polyclonal FBXO11 (A301-177A, A301-178A Bethyl Laboratories), rabbit polyclonal Fbxo11 produced by Covalab UK [8], rabbit polyclonal p53 (sc-6243 Santa Cruz Biotechnology), agarose-conjugated mouse monoclonal p53 (sc-126 AC), rabbit polyclonal Ki67 (VP-K451 Vector Laboratories), rabbit polyclonal cleaved caspase-3 antibody (9661 Cell Signaling Technology).
###end p 63
###begin title 64
Immunostaining
###end title 64
###begin p 65
###xml 713 719 <span type="species:ncbi:9986">Rabbit</span>
###xml 779 783 <span type="species:ncbi:9925">goat</span>
For immunohistochemical analysis, the avidin-biotin complex (ABC) method was used for all the antibody stainings except for the TGF-beta3 antibody. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in isopropanol for 20 min. Slides for Ki67, cleaved caspase-3, TGFbeta-RII and SMURF2 antibodies were pre-treated by boiling in a microwave in 10 mM sodium citrate buffer pH 6 for 14 min. Slides for Fbxo11 were pre-treated by boiling in a microwave in water for 14 min. After pre-treatment the slides were cooled at room temperature for 20 min and rinsed with phosphate-buffered saline. To inhibit non-specific endogenous biotin staining, the DAKO Biotin Blocking System was used (DAKO, X0590). Rabbit ABC Staining system (sc-2018 Santa Cruz Biotechnology) and goat ABC staining system (sc-2023 Santa Cruz Biotechnology) were used to develop the specific signals with all the antibodies except for TGF-beta3. The antibody incubations were as follow: TGFbeta-RII 1:100 dilution and SMURF2 1:200 dilution for 30 min; Fbxo11 1:200 dilution for 1 h, TGFbeta-RI, Smad2, pSmad2 (Ser 465/467), Smad3 and Smad4 overnight using a 1:200 dilution; Ki67 was incubated for 1 h at room temperate using a 1:1000 dilution, and cleaved caspase-3 for 1 h in 1:200 dilution. The slides were counterstained with haematoxylin.
###end p 65
###begin p 66
###xml 90 96 <span type="species:ncbi:9913">bovine</span>
###xml 225 231 <span type="species:ncbi:9986">rabbit</span>
For the immunohistochemical analysis with TGF-beta3 antibody, slides were blocked with 5% bovine serum albumin, incubated with the antibody overnight using a 1:200 dilution, washed with phosphate-buffered saline, and an anti-rabbit FITC-conjugated antibody (Sigma, F7512) was used as a secondary antibody for 30 min at room temperature in 1:160 dilution. Sections were washed with phosphate-buffered saline, mounted in Vectashield mounting medium (Vector Laboratories) and the staining was observed by fluorescence microscopy. Negative control sections were incubated with serum instead of the antibody and otherwise processed identically.
###end p 66
###begin title 67
Immunoprecipitation
###end title 67
###begin p 68
###xml 941 945 <span type="species:ncbi:9925">goat</span>
###xml 965 970 <span type="species:ncbi:10090">mouse</span>
Protein samples from lungs of E15.5 wild-type embryos were prepared by homogenizing in phosphate buffer solution, containing 1% triton X100, 0.5% deoxycholic acid and cocktail of protease inhibitors. The samples were incubated with 2 mM 3,3'-Dithiobis [sulfosuccinimidylpropionate] (DTSSP) cross-linker for 30 min at room temperature and treated as described by the manufacturer (PIERCE, 21578). Total protein extract of 1 mg was pre-cleared with 15 mul Sepharose-protein G beads (Sigma) for 1 h at 4degreesC with rotation. The pre-cleared extract was incubated with 4 mug of antibody (Smad 2, p53) overnight at 4degreesC. Twenty microlitres of protein G beads was added and allowed to bind for 3 h at 4degreesC with rotation. Beads were washed four times with 500 mul of extraction buffer and resuspended in electrophoresis loading buffer/reducing agent (NuPAGE, Invitrogen). As a negative control, an identical reaction was prepared where goat IgG (for Smad2) or mouse IgG (for p53) was used instead of the specific antibody. Cross-linking reversal was achieved by incubation at 37degreesC for 30 min, after which samples were heated at 70degreesC for 10 min and resolved in NuPAGE 7% Tris-Acetate gels (Invitrogen). Only one third of the total reaction was loaded per lane.
###end p 68
###begin title 69
Nuclear and cytoplasmic fractionation
###end title 69
###begin p 70
For the fractionation CelLytic NuCLEAR Extraction kit (Sigma, NXTRACT) was used. E15.5 lungs were lysed in 1x lysis buffer containing protease and phosphatase inhibitors using a glass homogenizer. Nuclei were pelleted by centrifugation and the cytoplasmic fraction obtained by retaining the supernatant. The nuclear extracts were obtained by resuspending the nuclei pellet in extraction buffer containing protease and phosphatase inhibitors, rocking the pellet for 30 min and subsequent centrifugation. Twenty micrograms of each protein sample was loaded on each lane.
###end p 70
###begin title 71
Western blot
###end title 71
###begin p 72
###xml 260 266 <span type="species:ncbi:9986">rabbit</span>
Gels were blotted onto PVDF (GE Healthcare) and blocked in phosphate-buffered saline containing 5% dry skimmed milk and 0.1% Tween 20. Antibodies were diluted in blocking solution at 1:250 (anti-p53), 1:500 (anti-pSmad2), 1:500 (anti-FBOX11) or 1:10,000 (anti-rabbit-HRP). Incubation with primary antibodies proceeded overnight at 4degreesC and with secondary antibody for 1 h at room temperature. Membranes were washed four times between antibodies and after secondary antibody in phosphate-buffered saline and 0.1% Tween 20. ECL Plus (GE Healthcare) was used as detection system.
###end p 72
###begin title 73
Data analysis
###end title 73
###begin p 74
###xml 123 127 <span type="species:ncbi:10090">mice</span>
We used chi-squared test to compare the difference between the observed and the expected number of the double heterozygous mice from the two crosses. To evaluate the probability of the calculated chi-squared value the chidist function in Excel was used.
###end p 74
###begin title 75
Competing interests
###end title 75
###begin p 76
The authors declare that they have no competing interests.
###end p 76
###begin title 77
Authors' contributions
###end title 77
###begin p 78
###xml 330 334 <span type="species:ncbi:10090">mice</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
HT carried out the immunostaining analysis, some of the proteomics analysis, contributed to the design of the study and the interpretation of the results and participated in drafting the manuscript. RH contributed to the analysis and discussion of the results. SM participated in the phenotyping and the genotyping of some of the mice, and MRR and HH performed most of the immunoprecipitations and western blot analysis and contributed to the interpretation of the results from these studies. CD helped with the study of the lung phenotype of the mice and contributed to the interpretations of the results. SDMB contributed to the design of the study, interpretation of results and participated in drafting the manuscript. All authors read and approved the final manuscript.
###end p 78
###begin title 79
Supplementary Material
###end title 79
###begin title 80
Additional file 1
###end title 80
###begin p 81
###xml 0 44 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunolocalization of TGF&#946;R-II and Smurf2</bold>
###xml 139 144 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Jf/Jf</italic>
Immunolocalization of TGFbetaR-II and Smurf2. Sections through E15.5 palate, E16 eyelids and E15.5 lungs of wild-type (WT) and homozygote (Jf/Jf) embryos, immunohistochemically stained with antibodies against TGFbetaR-II (upper panel) and Smurf2 (lower panel). Scale bars 20, 50 and 200 mum as indicated.
###end p 81
###begin p 82
Click here for file
###end p 82
###begin title 83
Acknowledgements
###end title 83
###begin p 84
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
This work was funded by the MRC. The authors would like to thank Caroline Barker, Jennifer Corrigan, Adele Seymour, Elizabeth Darley and Terry Hacker for histology services, David Shipston and Jim Humphreys for necropsy skills and Tim Randall, Lucie Vizor and Sara Wells for technical support. The authors are also grateful to Liz Robertson for the Smad2 knockout mice and to Lawrence Donehower for the p53 knockout mice.
###end p 84
###begin article-title 85
The aetiology of otitis media with effusion: a review
###end article-title 85
###begin article-title 86
Epidemiologic patterns in childhood hearing loss: a review
###end article-title 86
###begin article-title 87
Chronic and recurrent otitis media: a genome scan for susceptibility loci
###end article-title 87
###begin article-title 88
The heritability of otitis media: a twin and triplet study
###end article-title 88
###begin article-title 89
The genetic component of middle ear disease in the first 5 years of life
###end article-title 89
###begin article-title 90
###xml 99 104 <span type="species:ncbi:10090">mouse</span>
A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse
###end article-title 90
###begin article-title 91
###xml 9 14 <span type="species:ncbi:10090">mouse</span>
The deaf mouse mutant Jeff (Jf) is a single gene model of otitis media
###end article-title 91
###begin article-title 92
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse
###end article-title 92
###begin article-title 93
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Mutation at the Evi1 locus in Junbo mice causes susceptibility to otitis media
###end article-title 93
###begin article-title 94
Systematic analysis and nomenclature of mammalian F-box proteins
###end article-title 94
###begin article-title 95
The F-box protein family
###end article-title 95
###begin article-title 96
###xml 64 74 <span type="species:ncbi:6239">C. elegans</span>
DRE-1: an evolutionarily conserved F box protein that regulates C. elegans developmental age
###end article-title 96
###begin article-title 97
FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues
###end article-title 97
###begin article-title 98
FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity
###end article-title 98
###begin article-title 99
Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads
###end article-title 99
###begin article-title 100
TGF-beta signal transduction in oro-facial health and non-malignant disease (part I)
###end article-title 100
###begin article-title 101
A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure
###end article-title 101
###begin article-title 102
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development
###end article-title 102
###begin article-title 103
Mechanisms of TGF-beta signaling from cell membrane to the nucleus
###end article-title 103
###begin article-title 104
Controlling TGF-beta signaling
###end article-title 104
###begin article-title 105
Ubiquitin-dependent regulation of TGFbeta signaling in cancer
###end article-title 105
###begin article-title 106
Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation
###end article-title 106
###begin article-title 107
A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation
###end article-title 107
###begin article-title 108
Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase
###end article-title 108
###begin article-title 109
Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in t ransforming growth factor-beta signaling
###end article-title 109
###begin article-title 110
Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins
###end article-title 110
###begin article-title 111
MFB-1, an F-box-type ubiquitin ligase, regulates TGF-beta signalling
###end article-title 111
###begin article-title 112
Arkadia enhances Nodal/TGF-beta signaling by coupling phospho-Smad2/3 activity and turnover
###end article-title 112
###begin article-title 113
Transforming growth factor-beta 3 is required for secondary palate fusion
###end article-title 113
###begin article-title 114
TGF-beta3-dependent SMAD2 phosphorylation and inhibition of MEE proliferation during palatal fusion
###end article-title 114
###begin article-title 115
Palate development
###end article-title 115
###begin article-title 116
###xml 48 54 <span type="species:ncbi:10090">murine</span>
Differential expression of TGF beta isoforms in murine palatogenesis
###end article-title 116
###begin article-title 117
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction
###end article-title 117
###begin article-title 118
###xml 60 66 <span type="species:ncbi:9606">humans</span>
Association of MSX1 and TGFB3 with nonsyndromic clefting in humans
###end article-title 118
###begin article-title 119
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Pathogenesis of cleft palate in TGF-beta3 knockout mice
###end article-title 119
###begin article-title 120
Transforming growth factor-beta3 regulates transdifferentiation of medial edge epithelium during palatal fusion and associated degradation of the basement membrane
###end article-title 120
###begin article-title 121
Medial edge epithelial cell fate during palatal fusion
###end article-title 121
###begin article-title 122
###xml 34 38 <span type="species:ncbi:10090">mice</span>
Eyelid growth and fusion in fetal mice. A scanning electron microscope study
###end article-title 122
###begin article-title 123
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
Eyelid development, fusion and subsequent reopening in the mouse
###end article-title 123
###begin article-title 124
Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction
###end article-title 124
###begin article-title 125
MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation
###end article-title 125
###begin article-title 126
The control of cell motility and epithelial morphogenesis by Jun kinases
###end article-title 126
###begin article-title 127
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
Lung development in the mouse embryo
###end article-title 127
###begin article-title 128
Lung development and fetal lung growth
###end article-title 128
###begin article-title 129
Transcriptional control of lung morphogenesis
###end article-title 129
###begin article-title 130
###xml 85 90 <span type="species:ncbi:9606">human</span>
TGF-beta signaling is dynamically regulated during the alveolarization of rodent and human lungs
###end article-title 130
###begin article-title 131
###xml 9 14 <span type="species:ncbi:10090">mouse</span>
Abnormal mouse lung alveolarization caused by Smad3 deficiency is a developmental antecedent of centrilobular emphysema
###end article-title 131
###begin article-title 132
Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II
###end article-title 132
###begin article-title 133
Association of the FBXO11 gene with chronic otitis media with effusion and recurrent otitis media: the Minnesota COME/ROM Family Study
###end article-title 133
###begin article-title 134
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo
###end article-title 134
###begin article-title 135
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
###end article-title 135

